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Abstract: Background: DNA methylation in sputum has been an attractive candidate biomarker
for the non-invasive screening and detection of lung cancer. Materials and Methods: Databases
including PubMed, Ovid, Cochrane library, Web of Science databases, Chinese Biological Medicine
(CBM), Chinese National Knowledge Infrastructure (CNKI), Wanfang, Vip Databases and Google
Scholar were searched to collect the diagnostic trials on aberrant DNA methylation in the screening
and detection of lung cancer published until 1 December 2016. Indirect comparison meta-analysis
was used to evaluate the diagnostic value of the included candidate genes. Results: The systematic
literature search yielded a total of 33 studies including a total of 4801 subjects (2238 patients with
lung cancer and 2563 controls) and covering 32 genes. We identified that methylated genes in sputum
samples for the early screening and auxiliary detection of lung cancer yielded an overall sensitivity
of 0.46 (0.41–0.50) and specificity of 0.83 (0.80–0.86). Combined indirect comparisons identified the
superior gene of SOX17 (sensitivity: 0.84, specificity: 0.88), CDO1 (sensitivity: 0.78, specificity: 0.67),
ZFP42 (sensitivity: 0.87, specificity: 0.63) and TAC1 (sensitivity: 0.86, specificity: 0.75). Conclusions:
The present meta-analysis demonstrates that methylated SOX17, CDO1, ZFP42, TAC1, FAM19A4,
FHIT, MGMT, p16, and RASSF1A are potential superior biomarkers for the screening and auxiliary
detection of lung cancer.
Keywords: DNA methylation; lung cancer; sputum; detection; meta-analysis; indirect efficacy
comparison
1. Introduction
Lung cancer is the leading cause of malignant tumor death, with the morbidity and mortality of
lung cancer gradually increasing over the past decades [1]. Only 13% of lung cancer patients survive
more than 5 years, and the mortality is close to the morbidity (the ratio of mortality to morbidity
is 0.87) [1–3]. Despite research on the diagnosis of lung cancer and the use of increasingly advanced
technology in its treatment, the prognosis remains poor because of the predominant diagnosis of III,
IV-stage disease [3]. Therefore, early diagnosis, auxiliary detection, and treatment have become a
major focus to reduce the mortality caused by lung cancer.
With the emergence and development of molecular epidemiology, which opens the “black box”
of the disease process, molecular biomarkers have much potential to improve the understanding
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of the occurrence, development, and prognosis of disease for the early detection of these lesions
at the pre-invasive stage, even predicting the progress of the disease [4,5]. Nowadays, it is clearly
acknowledged that genetic alterations are accompanied by equally important epigenetic modifications
in the pathogenesis of lung cancer [6,7]. In particular, DNA methylation is one of the earliest epigenetic
modifications; it is closely associated with the occurrence and development of lung cancer, and it
appears earlier than obvious malignant phenotype [7]. Abundant evidence manifests that a variety
of well-known DNA methylations can be used as a promising biomarker for the early diagnosis of
lung cancer, such as p16 [8], RASSF1A [9], APC [10], MGMT [11], DAPK [12] and RARβ [13]. Many
studies have demonstrated that the aberrant methylation of some genes in sputum samples could be a
novel “remote medium” for the early detection of lung cancer, which avoids the necessity of invasive
procedures [5,14]. The development of next-generation sequencing technology and the maturation
of methylation detection technology [15,16] have made methylation detection much more stable and
cheaper, and could provide the necessary conditions for clinical utility. Taken together, findings suggest
that methylation could serve as efficient diagnostic biomarkers for lung cancer.
However, the DNA methylation of specific genes in sputum samples do not yet provide a
convincing and superior gene panel with high sensitivity and specificity for clinical utility in lung
cancer. In addition, there was still no comparative evaluation on the diagnostic accuracy of methylation
in sputum samples for the screening and detection of lung cancer. Recently, network meta-analysis
has been developed to assess the comparative effectiveness of several interventions and to synthesize
evidence across a network of studies [17,18]. This method makes it possible to estimate the comparative
diagnostic accuracy of multiple biomarkers which have not been directly compared with each other
in one study but have been reported by multiple studies under a common comparator. Therefore,
we performed a network meta-analysis to indirectly compare the efficacy of the DNA methylation of
multiple genes in the diagnosis of lung cancer.
2. Materials and Methods
We followed the reporting guidelines of the Preferred Reporting Items for Systematic Reviews
and Meta-Analysis (PRISMA) statement when conducting this review. The PRISMA statement has
guidelines that include a four-phase flow diagram to systematically guide the inclusion and exclusion
of research papers [19]. In addition, the guidelines provide a 27-item checklist that describes the
requirements per review section (e.g., title, abstract, introduction, methods, results, discussions,
and funding) to ensure that systematic reviews are properly conducted and reported [19].
2.1. Search Strategy
We conducted a comprehensive literature search in PubMed, Ovid, Cochrane library, Web of
Science databases, Chinese Biological Medicine (CBM), Chinese National Knowledge Infrastructure
(CNKI), Wanfang, Vip Databases, and Google Scholar. The main search terms included: lung
cancer or lung carcinoma or non-small cell lung cancer or “NSCLC”, “sputum or flema”,
“diagnostic”, “sensitivity and specificity” and “methylation or hypermethylation or hypomethylation
or demethylation”. All articles published until December 2016 were considered. In addition,
the reference lists of all identified studies were manually searched to identify any additional studies.
2.2. Inclusion Criteria and Exclusion Criteria
The articles, which could not be excluded based on the title and abstract, were retrieved for
full-text review. Studies were included in this meta-analysis if they met the following criteria: (1) the
diagnostic potential of sputum DNA methylation for lung cancer; (2) study design being case-control;
(3) the patients being diagnosed with lung cancer by pathology; (4) provided data on the numbers of
true positives (TP), false positives (FP), true negatives (TN), and false negatives (FN); (5) the methods of
detecting methylation based on methylation-specific polymerase chain reaction (MSP) or quantitative
methylation-specific PCR (qMSP).
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Studies were excluded from the meta-analysis for the following reasons: (1) abstracts, letters,
reviews, expert opinions, case reports, or nonclinical studies; (2) studies had duplicate or overlapping
data; (3) study was based on tissue, blood, or animals.
2.3. Data Extraction and Quality Assessment
Data extraction was conducted in duplicate by two investigators (Di Liu and Hongli Peng) based
on title, abstract, author, year of publication, country of origin, sample size, assay methods, and
diagnostic performance (sensitivity (SEN), specificity (SPE), TP, FP, FN, TN), target gene(s), and the
score of the quality assessment of studies of diagnostic accuracy (QUADAS) [20] and the standards for
reporting of diagnostic accuracy (STARD) [21]. Any disagreements in data extraction were resolved
by consensus.
STARD and QUADAS guidelines were utilized to assess the methodological quality of each study.
There are 25 items in the STARD initiative checklist, and a score of 1 was given when the item was
yielded [21]. Fourteen items were included in the QUADAS tool, whereby a score of 1 was given
when a specific item was fulfilled, 0 if this item was unclear, and −1 for the item not achieved [20].
All of these studies were evaluated independently and discussed by the reviewers until a consensus
was reached.
2.4. Statistical Analysis
We used standard methods recommended for the direct meta-analysis which estimated the
diagnostic test evaluation of DNA methylation compared with the gold standard [22]. The number of
TP, TN, FP, and FN were retrieved from each article. The SEN, SPE, positive likelihood ratio (PLR),
negative likelihood ratio (NLR), diagnostic odds ratio (DOR) estimates with 95% confidence interval
(CI) from each study were analyzed using a random-effect model and the bivariate summary receiver
operating characteristic (SROC) curve was generated. The area under the curve (AUC) represents
an analytical summary of the test performance and illustrates the trade-off between sensitivity and
specificity [23]. The heterogeneity among studies was assessed on the basis of the Chi Square test using
the Cochran Q statistic. The I2 statistic, which measures the extent of inconsistency between studies,
was also assessed [24]. Spearman’s correlation coefficient of logarithm sensitivity and 1-specificity for
each gene was assessed to determine the threshold effect [25]. Analyses were performed using two
statistical software programs (Meta-Disc 1.4 for Windows and Stata version 12.0, Stata Corp, College
Station, TX, USA).
For indirect comparisons, the comparative diagnostic accuracy of all biomarkers was estimated
according to common comparator (the gold standard). We did not assume consistency (which was
evaluated by comparing the direct estimates with the indirect estimates for each comparison) of two
biomarkers without direct analyses. We took the step-wise approach, which was suitable for the
simple star-network meta-analysis to obtain an indirect analysis. The Deeks’ test and Egger’s test were
utilized to estimate the funnel plot asymmetry and the publication bias [26]. The indirect meta-analysis
was conducted using indirect treatment comparison (ITC) software and Stata 12.0 (Stata Corp, College
Station, TX, USA) [27]. A two-sided p-value of less than 0.05 was considered significant.
3. Results
3.1. Subsection
3.1.1. Study Characteristics and Quality of Included Studies
The flowchart of included studies was presented in Figure 1. A total of 424 studies were
preliminarily reviewed, of which 33 were available for the indirect meta-analysis [5,14,28–58].
The characteristics of each study are shown in Table 1, including name of the study, number of patients
and controls, biomarkers, and quality assessment based on STARD and QUADAS. The systematic
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literature search yielded a total of 33 studies including a total of 4801 subjects (2238 patients with lung
cancer and 2563 controls) and covering 32 genes (P16, RASSF1A, APC, MGMT, PAX5, CGB, GATA,
DAPK, RARβ, MAGE, HOXA, 3OST2, PRDM14, FAM19A4, PHACTR3, PCDH20, CXCL, Dal-1, Dab2,
Dcr2, SULF2, Kifla, Jph3, SOX17, CDO1, ZFP42, TAC1, CDH1, H-cadherin, FHIT, RASSF2, TCF2l).
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Table 1. Baseline characteristics of all included studies.  
Study/Year Country Cases/Controls Biomarkers STARD QUADAS
Destro/2004 [41] Italy 24/100 p16 21 12 
Zhang/2004 [48] China 44/20 p16 18 8 
Wang/2004 [57] China 34/21 p16 17 7 
Konno/2004 [31] Japan 78/94 p16, APC, RARβ 20 11 
Belinsky/2005 [39] USA 53/118 
p16, MGMT, RASSF1A, DAP, H-
cadherin, PAX5 
20 9 
Olaussen/2005 [32] France 20/17 HOXA9, p16, MAGE 17 8 
Cirincione/2006 [44] Italy 18/112 RARβ, p16, RASSF1A 15 7 
Wang/2006 [45] China 79/22 FHIT, p16, RARβ 20 10 
Liu/2006 [54] China 77/30 MGMT 18 8 
Belinsky/2006 [47] USA 98/92 
p16, PAX5, MGMT, DAPK, GATA, 
RASSF1ASFRP1, HLHPBETA3, 
IGFBP3HCAD, LAMC2 
20 10 
Georgiou/2007 [30] Greece 80/40 p16 16 9 
Hsu/2007 [5] China 82/37 p16, RARβ 16 7 
Liu/2008 [29] China 58/107 p16 18 10 
Guo/2008 [53] China 100/50 p16 16 7 
Van der Drift/2008 
[33] 
Netherlands 28/68 RASSF1A 19 11 
Hu/2009 [51] China 42/25 p16 16 9 
Ye/2010 [49] China 30/27 RASSF1A 16 7 
Zhang/2010 [49] China 82/25 RASSF1A, p16, DAPK 18 8 
Hwang/2011 [36] Korea 76/109 HOXA 20 9 
Song/2011 [28] China 42/9 p16, MGMT 17 8 
Zhang/2011 [52] China 41/15 p16 17 9 
Hang/2011 [38] China 47/24 FHIT 20 8 
Sun/2012 [55] China 120/120 p16, RASSF1A 19 7 
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a le 1. aseline characteristics of all included studies.
Study/Year Country Cases/Controls Biomarkers STARD QUADAS
Destro/2004 [41] Italy 24/100 p16 21 12
Zhang/2004 [48] China 44/20 p16 18 8
Wang/2004 [57] China 34 21 p16 17 7
Konno/2004 [31] Japan 78/94 p16, APC, RARβ 20 11
Belinsky/2005 [39] USA 53/118 p16, MGMT, RASSF1A, DAP,H-cadherin, PAX5 20 9
Olaussen/2005 [32] France 20 17 HOXA9, p16, MAGE 17 8
Cirincione/2006 [44] Italy 18/112 RARβ, p16, RASSF1A 15 7
Wang/2006 [45] China 79/22 FHIT, p16, RARβ 20 10
Liu/2006 [54] China 77/30 MGMT 18 8
Belinsky/2006 [47] USA 98/92
p16, PAX5, MGMT, DAPK, GATA,
RASSF1ASFRP1, HLHPBETA3,
IGFBP3HCAD, LAMC2
20 10
Georgiou/2007 [30] Greece 80/40 p16 16 9
Hsu/2007 [5] China 82/37 p16, RARβ 16 7
Liu/2008 [29] China 58/107 p16 18 10
Guo/2008 [53] China 100 50 p16 16 7
Van der Drift/2008 [33] Netherlands 28/68 RASSF1A 19 11
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Table 1. Cont.
Study/Year Country Cases/Controls Biomarkers STARD QUADAS
Hu/2009 [51] China 42/25 p16 16 9
Ye/2010 [49] China 30/27 RASSF1A 16 7
Zhang/2010 [49] China 82/25 RASSF1A, p16, DAPK 18 8
Hwang/2011 [36] Korea 76/109 HOXA 20 9
Song/2011 [28] China 42/9 p16, MGMT 17 8
Zhang/2011 [52] China 41/15 p16 17 9
Hang/2011 [38] China 47/24 FHIT 20 8
Sun/2012 [55] China 120/120 p16, RASSF1A 19 7
Hubers/2012 [46] TheNetherlands 53/47 RASSF1A, APC, CYGB 18 10
Guzmán/2012 [14] Chile 26/33 p16, CDH1, MGMT 18 11
Shin/2012 [42] Korea 65/30 MAGE, p16 17 9
Leng/2012 [35] USA 64/64
p16, MGMT, DAPK, PAX5, GATA, Dal-1,
PCDH20, Jph3, Kifla, SULF2, RASSFlA,
GATA, Dab2, Dcr2, RASSF2, TCF2l
20 11
Leng/2012 [35] USA 40/90
p16, MGMT, DAPK, PAX5, GATA, Dal-1,
PCDH20, Jph3, Kifla, SULF2, CXCL,
RASSFlA, Dab2, Dcr2, RASSF2, TCF2l
20 11
Pan/2013 [56] China 20/13 p16 19 8
Hubers/2014 [34] TheNetherlands 20/31
RASSF1A, APC, CYGB, 3OST, PRDM14,
FAM19A4, PHACTR3 19 8
Hubers/2014 [43] TheNetherlands 98/90 RASSF1A, APC, CYGB 20 10
Hubers/2014 [43] TheNetherlands 60/445 RASSF1A, APC, CYGB 20 10
Hubers/2015 [58] TheNetherlands 73/86
RASSF1A, APC, CYGB, 3OST2, PRDM14,
FAM19A4, PHACTR3 21 11
Hubers/2015 [58] TheNetherlands 159/154
RASSF1A, APC, CYGB, 3OST2, PRDM14,
FAM19A4, PHACTR3 21 11
Su/2016 [40] China 117/174 RASSF1A, 3OST2, PRDM14 18 7
Hulbert/2016 [37] USA 90/24 SOX17, TAC1, CDO1, HOXA, ZFP42 16 9
STARD: Standards for reporting of diagnostic accuracy; QUADAS: Quality assessment of studies of
diagnostic accuracy
3.1.2. Summary Performance of Diagnostic Estimates
As shown in Table 2, of the 32 genes, the SEN (sensitivity) ranged from 0.03 to 0.87 (pooled 0.46;
95% CI: 0.41–0.50), whereas SPE ranged from 0.25 to 0.99 (pooled 0.83; 95% CI: 0.80–0.86). The PLR
(positive likelihood ratio) ranged from 1.03 to 6.76 (pooled 2.72; 95% CI: 2.32–3.22),NLR (negative
likelihood ratio) ranged from 0.18 to 0.98 (pooled 0.64; 95% CI: 0.60–0.68), and DOR (diagnostic odds
ratio) ranged from 1.05 to 38.00 (pooled 4.28; 95% CI: 3.50–5.20). Of the 32 genes, the higher of SEN
were ZFP42: 0.87 (0.78–0.93), TAC1: 0.86 (0.77–0.92), SOX17: 0.84 (0.75–0.91), FAM19A4: 0.80 (0.74–0.85),
and HOXA: 0.79 (0.63–0.89); whereas the higher of PLR were SOX17: 6.76 (2.34–19.54), FHIT: 5.93
(2.29–15.36), RASSF1A: 5.61 (3.73–8.43), MGMT: 4.78 (1.47–15.55), and p16: 4.71 (2.53–8.78).
The graph of the SROC (summary receiver operating characteristic) cure is shown in Figure 2,
which demonstrates the trade-off between SEN and SPE values in multiple studies. The SROC
curve results showed that AUC (area under the curve) of 32 different methylated genes was 0.69
(0.64–0.73), indicating the ability of 32 pooled gene methylations to differentiate lung cancer patients
from non-lung-cancer patients with a mid-level accuracy.
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Table 2. The summary performance of diagnostic estimates.
Genes Study-Case/Control SEN (95% CI) SPE (95% CI) PLR (95% CI) NLR (95% CI) DOR (95% CI)
CDH1 1–26/33 0.35 (0.17–0.56) 0.70 (0.51–0.84) 1.14 (0.55–2.39) 0.94 (0.66–1.00) 1.22 (0.41–3.65)
SOX17 1–90/24 0.84 (0.75–0.91 0.88 (0.68–0.97) 6.76 (2.34–19.54) 0.18 (0.11–0.29) 38.00 (9.98–144.73)
CDO1 1–90/24 0.78 (0.68–0.86) 0.67 (0.45–0.84) 2.32 (1.31–4.15) 0.33 (0.21–0.54) 7.00 (2.62–18.72)
ZFP42 1–90/24 0.87 (0.78–0.93) 0.63 (0.41–0.81) 2.31 (1.37–3.90) 0.21 (0.12–0.39) 10.83 (3.88–30.22
TAC1 1–90/24 0.86 (0.77–0.92) 0.75 (0.53–0.90) 3.42 (1.70–6.88) 0.19 (0.11–0.33) 17.77 (5.94–53.12)
H-cadherin 1–53/118 0.50 (0.23–0.77) 0.57 (0.46–0.68) 1.18 (0.66–2.11) 0.87 (0.50–1.00) 1.35 (0.43–4.22)
FHIT 2–126/46 0.52 (0.43–0.61) 0.91 (0.79–0.98) 5.93 (2.29–15.36) 0.53 (0.43–0.65) 11.19 (3.79–33.06)
PCDH20 2–104/154 0.58 (0.48–0.67) 0.49 (0.41–0.58) 1.14 (0.91–1.43) 0.86 (0.65–1.00) 1.33 (0.80–2.19)
Dab2 2–104/154 0.03 (0.01–0.08) 0.99 (0.95–1.00) 2.22 (0.38–13.06) 0.98 (0.95–1.00) 2.26 (0.37–13.75)
Dcr2 2–104/154 0.41 (0.32–0.51) 0.60 (0.52–0.68) 1.03 (0.76–1.38) 0.98 (0.80–1.00) 1.05 (0.63–1.73)
SULF2 2–104/154 0.51 (0.41–0.61) 0.57 (0.49–0.65) 1.19 (0.91–1.55) 0.86 (0.68–1.00) 1.39 (0.84–2.28)
Kifla 2–104/154 0.44 (0.34–0.54 0.62 (0.54–0.70 1.17 (0.87–1.58) 0.89 (0.72–1.00) 1.31 (0.79–2.18)
Dal-1 2–104/154 0.30 (0.21–0.39 0.86 (0.80–0.91 2.17 (1.32–3.55) 0.82 (0.71–0.94) 2.65 (1.42–4.94)
Jph3 2–104/154 0.31 (0.23–0.41 0.79 (0.721–0.85 1.47 (0.97–2.22) 0.87 (0.75–1.00) 1.68 (0.96–2.95)
RASSF2 2–104/154 0.08 (0.03–0.15) 0.95 (0.91–0.98) 1.69 (0.63–4.52) 0.97 (0.91–1.00) 1.75 (0.61–4.98)
TCF2l 2–104/154 0.29 (0.20–0.39) 0.71 (0.63–0.78) 0.99 (0.67–1.46) 1.01 (0.86–1.00) 0.98 (0.57–1.70)
CXCL 2–80/180 0.36 (0.26–0.48 0.79 (0.72–0.85 1.72 (1.15–2.58) 0.81 (0.67–0.97) 2.12 (1.19–23.79)
MAGE 4–202/118 0.45 (0.34–0.55 0.82 (0.56–0.94 2.44 (0.75–7.96 0.68 (0.47–0.99 3.60 (0.76–16.98
HOXA 4–276/174 0.79 (0.63–0.89) 0.50 (0.16–0.84) 1.56 (0.80–3.07) 0.43 (0.28–0.66) 3.63 (1.28–10.26)
RARβ 4–257/223 0.44 (0.29–0.60) 0.79 (0.58–0.91) 2.09 (0.93–4.70) 0.71 (0.52–0.98) 2.93 (0.99–8.69)
FAM19A4 3–252/271 0.80 (0.74–0.85 0.25 (0.20–0.30) 1.06 (0.97–1.16) 0.82 (0.59–1.00) 1.29 (0.86–1.96)
PHACTR3 3–252/271 0.60 (0.53–0.66 0.68 (0.62–0.73) 1.85 (1.52–2.27) 0.60 (0.50–0.71) 3.11 (2.17–4.45)
DAPK 5–337/389 0.45 (0.40–0.51) 0.79 (0.64–0.89) 2.16 (1.13–4.14) 0.69 (0.58–0.86) 3.12 (1.32–7.36)
3OST2 4–369/445 0.50 (0.45–0.55) 0.85 (0.82–0.88) 3.36 (2.63–4.30) 0.59 (0.53–0.66) 5.71 (4.10–7.96)
PRDM14 4–369/445 0.62 (0.57–0.67) 0.76 (0.72–0.80) 2.63 (2.19–3.17) 0.50 (0.43–0.57) 5.30 (3.91–7.17)
GATA 6–404/492 0.66 (0.31–0.90) 0.53 (0.33–0.71) 1.40 (1.16–1.69) 0.64 (0.34–1.21) 2.20 (1.01–4.83)
MGMT 8–447/460 0.42 (0.32–0.52) 0.91 (0.77–0.97) 4.78 (1.47–15.55) 0.64 (0.50–0.81) 7.48 (1.87–29.91)
PAX5 8–510/728 0.37 (0.29–0.45) 0.78 (0.70–0.84) 1.65 (1.28–2.12) 0.81 (0.74–0.90) 2.02 (1.45–2.83)
CYGB 6–453/853 0.51 (0.45–0.57) 0.79 (0.69–0.88) 2.39 (1.61–3.56) 0.62 (0.54–0.72) 3.83 (2.28–6.44)
APC 8–588/928 0.43 (0.34–0.53) 0.87 (0.71–0.95) 3.30 (1.67–6.51) 0.65 (0.59–0.72) 5.06 (2.55–10.04)
p16 24–1357/1249 0.48 (0.40–0.56) 0.90 (0.82–0.95) 4.71 (2.53–8.78) 0.58 (0.50–0.68) 8.11 (3.94–16.70)
RASSF1A 17–1160/1767 0.28 (0.20–0.38) 0.95 (0.93–0.97) 5.61 (3.73–8.43) 0.76 (0.67–0.85) 7.40 (4.54–12.06)
Summary 33–2238/2563 0.46 (0.41–0.50) 0.83 (0.80–0.86) 2.72 (2.32–3.22) 0.64 (0.60–0.68) 4.28 (3.50–5.20)
DOR: Diagnostic odds ratio; NLR: Negative likelihood ratio; PLR: Positive likelihood ratio; SEN: Sensitivity; SPE:
Specificity. Bold text: The top five values.
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3OST2 4–369/445 0.50 (0.45–0.55) 0.85 (0.82–0.88) 3.36 (2.63–4.30) 0.59 (0.53–0.66) 5.71 (4.10–7.96) 
PRDM14 4–369/445 0.62 (0.57–0.67) 0.76 (0.72–0.80) 2.63 (2.19–3.17) 0.50 (0.43–0.57) 5.30 (3.91–7.17) 
GATA 6–404/492 0.66 ( .31 0.90) 0.53 (0.33–0.71) 1.40 (1.1 –1.69) 0.64 ( .34–1.21) 2.2  (1.01–4.83) 
MGMT 8–447/460 0.42 (0.32 .52) 0. 1 (0.77–0.97) 4.78 (1.47–15.55) 0.64 (0.50–0.81) 7.48 (1.87–29.91) 
PAX5 8–510/728 0.37 (0.29–0.45) 0.78 (0.70–0.84) 1.65 (1.28–2.12) 0.81 (0.74–0.90) 2.02 (1.45–2.83) 
CYGB 6–453/853 0.51 (0.45–0.57) 0.79 (0.69–0.88) 2.39 (1.61–3.56) 0.62 (0.54–0.72) 3.83 (2.28–6.44) 
APC 8–588/928 0.43 (0.34–0.53) 0.87 (0.71–0.95) 3.30 (1.67–6.51) 0.65 (0.59–0.72) 5.06 (2.55–10.04) 
p16 24–1357/1 49 0.48 (0.40 .56) 0.90 (0.82–0.95) 4.71 (2.53–8.78) 0.58 (0.50–0.68) 8.11 (3.94–16.70) 
RASSF1A 17–1160/1767 0.28 (0.20–0.38) 0.95 (0.93–0.97) 5.61 (3.73–8.43) 0.76 (0.67–0.85) 7.40 (4.54–12.06) 
Summary 33–2238/2563 0.46 (0.41–0.50) 0.83 (0.80–0.86) 2.72 (2.32–3.22) 0.64 (0.60–0.68) 4.28 (3.50–5.20) 
DOR: Diagnostic odds ratio; NLR: Negative likelihood ratio; PLR: Positive likelihood ratio; SEN: 
Sensitivity; SPE: Specificity. Bold text: The top five values. 
The graph of the SROC (summary receiver operating characteristic) cure is shown in Figure 2, 
which de onstrates the trade-off between SEN and SPE values in multiple studies. The SROC curve 
results showed that AUC (area under the curve) of 32 different methylate  genes was 0.69 (0.64–0.73), 
indicating the ability of 32 pooled gene methylations to differentiate lung cancer patients from non-
lung-cancer patients with a mid-level accuracy. 
 
Figure 2. Summary receiver operating characteristic (SROC) curve with pooled estimates 
of sensitivity, specificity, and area under the curve (AUC) on the diagnostic value of gene 
methylation in lung cancer. 
3.1.3. Indirect Comparisons of Diagnostic Analysis 
Figure 3 shows the star-network of comparisons for methylated genes (1–32) with the gold 
standard of being diagnosed with lung cancer (33). We established a network to compare the 
diagnostic accuracy of 32 methylated genes, with the results of indirect comparisons presented in 
Table S1. The OR and 95% CI of SOX17, TAC1, ZFP42, CDO1 differed significantly from the other 28 
methylated genes and were higher than 1, indicating that SOX17, TAC1, ZFP42, and CDO1 have a 
higher diagnostic accuracy. More information is shown in the supplemental content (Figures S1–S32). 
We combined indirect comparisons to evaluate the comparative efficacy of different methylated 
genes; the superior genes were performed by SOX17 (sensitivity: 0.84, specificity: 0.88), CDO1 
Figure 2. Sum ary receiver operating characteristic (SROC) curve with pooled estimates of sensitivity,
specificity, and area under the curve (AUC) on the diagnostic value of gene methylation in lung cancer.
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3.1.3. Indirect Comparisons of Diagnostic Analysis
Figure 3 shows the star-network of comparisons for methylated genes (1–32) with the gold
standard of being diagnosed with lung cancer (33). We established a network to compare the diagnostic
accuracy of 32 methylated genes, with the results of indirect comparisons presented in Table S1. The OR
and 95% CI of SOX17, TAC1, ZFP42, CDO1 differed significantly from the other 28 methylated genes
and were higher than 1, indicating that SOX17, TAC1, ZFP42, and CDO1 have a higher diagnostic
accuracy. More information is shown in the supplemental content (Figures S1–S32). We combined
indirect comparisons to evaluate the comparative efficacy of different methylated genes; the superior
genes were performed by SOX17 (sensitivity: 0.84, specificity: 0.88), CDO1 (sensitivity: 0.78, specificity:
0.67), ZFP42 (sensitivity: 0.87, specificity: 0.63), TAC1 (sensitivity: 0.86, specificity: 0.75) (Table 2).
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(sensitivity: 0.78, specificity: 0.67), ZFP42 (sensitivity: 0.87, specificity: 0.63), TAC1 (sensitivity: 0.86, 
specificity: 0.75) (Table 2). 
 
Figure 3. The star-network plot of different methylated genes for 1–32 (1/CDH1, 2/SOX17, 3/CDO1, 
4/ZFP42, 5/TAC1, 6/H-cadherin, 7/FHIT, 8/PCDH20, 9/Dab2, 10/Dcr2, 11/SULF2, 12/Kifla, 13/Dal-1, 
14/Jph3, 15/RASSF2, 16/TCF2l, 17/CXCL, 18/MAGE, 19/HOXA, 20/RARβ, 21/FAM19A4, 22/PHACTR3, 
23/DAPK, 24/3OST2, 25/PRDM14, 26/GATA, 27/MGMT, 28/PAX5, 29/CYGB, 30/APC, 31/p16, 
32/RASSF1A) and 33/the gold standard of being diagnosed with lung cancer. 
3.1.4. Test of Heterogeneity and Meta-Regression 
In the meta-analysis, computation of the Spearman’s rank correlation coefficient between the 
logit of sensitivity and that of 1-specificity of sputum DNA testing was 0.465 (p < 0.001), indicating 
the heterogeneity of threshold effect. We also investigated the non-threshold effects; the results 
indicated the existence of significant heterogeneity in the overall sensitivity (I2 = 91.2%, p < 0.001), 
specificity (I2 = 93.5%, p < 0.001), PLR (I2 = 85.4%, p < 0.001), NLR (I2 = 88.8%, p < 0.001), and DOR (I2 = 
72.6%, p < 0.001). Therefore, a bivariate binomial mixed model was applied to summarize the pooled 
estimates in this study. To determine the sources of heterogeneity, we performed meta-regression to 
test the effect of ethnicity (Asian/others), sample size (n = 0–100/101–200/201–), and the quality of 
study (low/medium/high). Multivariable regression showed that ethnicity (coefficient = −0.785, p = 
0.001) and the sample size (coefficient = −0.324, p = 0.036) had statistically significant differences, while 
the quality of study (coefficient = −0.074, p = 0.552) showed no significant difference. Then, we 
conducted subgroup analysis based on ethnicity and the sample size, as shown in Table 3. 
Table 3. Detailed information of subgroup analysis. 
Analysis SEN (95% CI) SPE (95% CI) PLR (95% CI) NLR (95% CI) DOR (95% CI)
Ethnicity      
Asian 0.46 (0.44–0.48) 0.84 (0.93–0.86) 4.04 (2.91–5.62) 0.61 (0.55–0.66) 6.50 (4.73–8.92) 
Others 0.47 (0.46–0.48) 0.75 (0.74–0.75) 1.88 (1.68–2.10) 0.72 (0.68–0.77) 2.92 (2.46–3.47) 
Sample size      
0–100 0.48 (0.46–0.51) 0.85 (0.83–0.88) 4.13 (2.80–6.08) 0.59 (0.54–0.65) 7.80 (5.22–11.65) 
101–200 0.45 (0.44–0.46) 0.75 (0.74–0.76) 1.78 (1.58–2.00) 0.73 (0.69–0.78) 2.75 (2.29–3.31) 
201– 0.51 (0.48–0.53) 0.76 (0.74–0.77) 2.52 (1.85–3.44) 0.65 (0.59–0.73) 3.94 (2.68–5.42) 
In addition, we performed a meta-regression to test the effect of ethnicity, sample size, and the 
quality of study with different genes. The results showed that ethnicity (coefficient = −1.117, p = 0.048) 
and the sample size (coefficient = −1.177, p = 0.026) were of statistically significant bias for p16, while 
not significant bias for other candidate genes (p > 0.050). 
Figure The star-network pl t o different methylat d genes for –32 ( /CDH1, 2/SOX17,
3/CDO1, 4/ZFP42, 5 TAC1, 6/H-cadherin, 7 FHIT, 8/PC H 0, 9/ ab , 0 Dcr2, 11/SULF2, 2 Kifla,
13/Dal-1, 14/Jph3, 15/RASSF2, 16/TCF2l, 17/CXCL, 18/MAGE, 19/HOXA, 20/RARβ, 1 FAM19A4,
22/PHACTR3, 23/DAPK, 24/3OST2, 25/PRDM14, 6 GATA, 27/MGMT, 28/PAX5, 29/CYGB, 30/APC,
31/p16, 32/RASSF1A) and 33/the gold standard of being iagnosed with lung cancer.
3.1.4. est of eterogeneity and eta-Regres ion
In the meta-analysi , computa ion of the Spearman’s rank correlation c efficient b twe n th logit
of sensitivity and that of 1-specificity of sputum DNA testing was 0.465 (p < 0.001), indicating the
heterog neity of threshold effect. W also inve tigated he non- reshold effects; th r sults indicated
the existence of significant heterogeneity in the overall sensitivity (I2 = 91.2%, p < 0.001), specificity
(I2 = 93.5%, p < 0.001) PLR (I2 = 85.4%, p < 0 001), NLR (I2 = 88.8%, p < 0.001), and DOR (I2 = 72.6%,
p < 0.001). Therefore, a bivariate binomial mixed model was applied to summarize the pool d estimat s
in his study. To determine th sources of heterogenei y, w performed meta-regression to test the
effec of thnicity (Asian/others), sample ize (n = 0–100/1 1–2 0/201–), and the quality of study
(low/mediu /high). Multivariable regr ssion showed that ethnicity (coefficient = −0.785, p = 0.001)
and the sample size (coefficient = −0.324, p = 0.036) had st ti ically significant differences, while the
quality of study (coefficient = −0.074, p = 0.552) showed no significant difference. Th n, w conducted
subgroup analysis based on ethnicity and the sample size, s shown in Table 3.
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Table 3. Detailed information of subgroup analysis.
Analysis SEN (95% CI) SPE (95% CI) PLR (95% CI) NLR (95% CI) DOR (95% CI)
Ethnicity
Asian 0.46 (0.44–0.48) 0.84 (0.93–0.86) 4.04 (2.91–5.62) 0.61 (0.55–0.66) 6.50 (4.73–8.92)
Others 0.47 (0.46–0.48) 0.75 (0.74–0.75) 1.88 (1.68–2.10) 0.72 (0.68–0.77) 2.92 (2.46–3.47)
Sample size
0–100 0.48 (0.46–0.51) 0.85 (0.83–0.88) 4.13 (2.80–6.08) 0.59 (0.54–0.65) 7.80(5.22–11.65)
101–200 0.45 (0.44–0.46) 0.75 (0.74–0.76) 1.78 (1.58–2.00) 0.73 (0.69–0.78) 2.75 (2.29–3.31)
201– 0.51 (0.48–0.53) 0.76 (0.74–0.77) 2.52 (1.85–3.44) 0.65 (0.59–0.73) 3.94 (2.68–5.42)
In addition, we performed a meta-regression to test the effect of ethnicity, sample size, and the
quality of study with different genes. The results showed that ethnicity (coefficient = −1.117, p = 0.048)
and the sample size (coefficient = −1.177, p = 0.026) were of statistically significant bias for p16, while
not significant bias for other candidate genes (p > 0.050).
Publication bias was evaluated by Deeks’ test and Egger’s test. The funnel plots for publication
bias showed no asymmetry (Figure 4). The result of Deeks’ test showed that p = 0.008, indicating that
publication bias could exist in the meta-analysis.
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26/GATA, 27/MGMT, 28/PAX5, 29/CYGB, 30/APC, 31/p16, 32/RASSF1A) and 33/the gold standard of 
being diagnosed with lung cancer. 
4. Discussion 
Lung cancer has become a global burden, further substantiating the need for early screening and 
auxiliary detection [1,3]. The key to accomplishing both these goals is the better understanding of the 
genes or pathways disrupted in causing lung cancer [6,45,59]. The fact that silencing genes through 
hypermethylation or activating genes through hypomethylation play an important role in the 
initiation and progression of lung cancer has stimulated the development of screening approaches to 
identify additional genes and pathways that are disrupted within the epigenome [59]. In addition, 
DNA methylation in sputum samples has the potential to serve as a non-invasive screening method 
for the identification of specific biomarkers, enabling the early detection of lung cancer [31,39]. 
In the direct meta-analysis, we identified that methylated genes in sputum samples for the early 
screening and auxiliary detection of lung cancer yielded an overall sensitivity of 0.46 at the same 
specificity of 0.83. Furthermore, the PLR (positive likelihood ratio) was 2.72, NLR (negative likelihood 
ratio) was 0.64, and DOR (diagnostic odds ratio) value was 4.28, and the AUC (area under the curve) 
was 0.69, indicating a mid-level accuracy. Therefore, we should pick the superior genes for clinical 
utility as diagnostic biomarkers for lung cancer. Combined indirect comparisons identified the 
superior genes as SOX17 (sensitivity: 0.84, specificity: 0.88), CDO1 (sensitivity: 0.78, specificity: 0.67), 
ZFP42 (sensitivity: 0.87, specificity: 0.63), and TAC1 (sensitivity: 0.86, specificity: 0.75). A single DNA 
methylation biomarker cannot be expected to detect all cases of lung cancer. Some studies 
demonstrated that combined multiple methylated genes could improve the diagnostic value of 
cancers [37,60]. We identified that the sensitivity value of methylated FAM19A4 and PLR value of 
methylated RASSF1A, FHIT, MGMT, and p16 are relatively high, suggesting that they are 
comprehensive parameters for the screening test [61]. In addition, methylated RASSF1A and p16 
genes are reported to be promising driving molecules in many cancers under the concept of precision 
medicine [9,62–67]. In addition, the methylation of FAM19A4, FHIT, and MGMT were reported to 
play important roles in the occurrence and deterioration of lung cancer [68–71]. Therefore, we 
Figure 4. Funnel plot of the publication bias (a) from Deeks’ test, the data is based on the article of cases
and controls. (b) From Egger’s test, the data is based on the article indirect comparisons of methylated
gene for 1–32 (1/CDH1, 2/SOX17, 3/CDO1, 4/ZFP42, 5/TAC1, 6/H-cadherin, 7/FHIT, 8/PCDH20,
9/Dab2, 10/Dcr2, 11/SULF2, 12/Kifla, 13/Dal-1, 14/Jph3, 15/RASSF2, 16/TCF2l, 17/CXCL, 18/MAGE,
19/HOXA, 20/RARβ, 21/FAM19A4, 22/PHACTR3, 23/DAPK, 24/3OST2, 25/PRDM14, 26/GATA,
27/MGMT, 28/PAX5, 29/CYGB, 30/APC, 31/p16, 32/RASSF1A) and 33/the gold standard of being
diagnosed with lung cancer.
4. Discussion
Lung cancer has become a global burden, further substantiating the need for early screening
and auxiliary detection [1,3]. The key to accomplishing both these goals is the better understanding
of the genes or pathways disrupted in causing lung cancer [6,45,59]. The fact that silencing genes
through hypermethylation or activating genes through hypomethylation play an important role in the
initiation and progression of lung cancer has stimulated the development of screening approaches
to identify additional genes and pathways that are disrupted within the epigenome [59]. In addition,
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DNA methylation in sputum samples has the potential to serve as a non-invasive screening method
for the identification of specific biomarkers, enabling the early detection of lung cancer [31,39].
In the direct meta-analysis, we identified that methylated genes in sputum samples for the
early screening and auxiliary detection of lung cancer yielded an overall sensitivity of 0.46 at the
same specificity of 0.83. Furthermore, the PLR (positive likelihood ratio) was 2.72, NLR (negative
likelihood ratio) was 0.64, and DOR (diagnostic odds ratio) value was 4.28, and the AUC (area
under the curve) was 0.69, indicating a mid-level accuracy. Therefore, we should pick the superior
genes for clinical utility as diagnostic biomarkers for lung cancer. Combined indirect comparisons
identified the superior genes as SOX17 (sensitivity: 0.84, specificity: 0.88), CDO1 (sensitivity: 0.78,
specificity: 0.67), ZFP42 (sensitivity: 0.87, specificity: 0.63), and TAC1 (sensitivity: 0.86, specificity:
0.75). A single DNA methylation biomarker cannot be expected to detect all cases of lung cancer.
Some studies demonstrated that combined multiple methylated genes could improve the diagnostic
value of cancers [37,60]. We identified that the sensitivity value of methylated FAM19A4 and PLR
value of methylated RASSF1A, FHIT, MGMT, and p16 are relatively high, suggesting that they are
comprehensive parameters for the screening test [61]. In addition, methylated RASSF1A and p16
genes are reported to be promising driving molecules in many cancers under the concept of precision
medicine [9,62–67]. In addition, the methylation of FAM19A4, FHIT, and MGMT were reported to play
important roles in the occurrence and deterioration of lung cancer [68–71]. Therefore, we advocate
that methylated SOX17, CDO1, ZFP42, TAC1, FAM19A4, FHIT, MGMT, p16, and RASSF1A are useful
in the screening and auxiliary detection of lung cancer.
To our knowledge, this study is the first systemic review and indirect meta-analysis to assess the
comparative diagnostic effectiveness of the methylation profile of multiple candidate gens in sputum
samples for the early screening and detection of lung cancer. According to the method of network
meta-analysis [18,27], we used indirect comparison to estimate the comparative diagnostic accuracy of
two methylated genes based on a common comparator (the gold standard of being diagnosed with
lung cancer). Therefore, the inconsistency between the direct and indirect comparison is not available
to address.
However, we observed a large degree of heterogeneity among studies investigating methylation
profile in sputum samples used for lung cancer. Threshold effect is one of the primary causes of
heterogeneity among diagnostic accuracy studies [24]. In the present meta-analysis, we found obvious
heterogeneity as a result of threshold effect, which may be caused by different genes. There is a
clear and unified cut-off value for methylation/unmethylation regardless of whether it is based on
qualitative analysis or quantitative analysis for each gene tested by the method of MSP [16]. Moreover,
we performed meta-regression to test the heterogeneity caused by ethnicity, sample size, and the
quality of study. The results suggested that study region (p = 0.001) and the sample size (p = 0.036)
might be a source of heterogeneity for this meta-analysis. The results of subgroup analyses showed
that large-sample studies had higher sensitivity than the small- and moderate-sample studies, while
studies in Asia had lower sensitivity than other regions.
In addition, publication bias could exist in the meta-analysis. This meta-analysis was only based
on published studies, therefore inducing the possibility of publication bias. The Deeks’ test and Egger’s
test not only detect publication bias, but also indicate the heterogeneity due to the effect of ethnicity,
sample size, the quality of study, etc. [72,73]. Therefore, we proposed that the heterogeneity was
potentially due to different genes, study region, and sample size. However, this speculation needs to
be investigated in the future study.
The present network meta-analysis included 33 articles and 32 candidate genes, with the majority
of genes only included in one article. These make it difficult to directly compare the diagnostic
efficacy among multiple genes; thus, only indirect comparisons were evaluated in this study. However,
the absence of direct comparisons may lead to bias. Pairwise meta-analysis and network meta-analysis
were carried out sequentially for direct and indirect comparisons of migraine headache days among
three interventions compared with those treated by three placebos, and the results showed that
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there was no significant inconsistency between the direct and indirect evidence for the majority of
comparisons [74]. Another network meta-analysis was performed to directly and indirectly compare
the effectiveness of several oral antidiabetic drugs in the prevention of cardiovascular mortality and
morbidity, and the results indicated that the inconsistency between direct and indirect estimates
of all-cause mortality, cardiovascular-related mortality, acute coronary syndrome, and myocardial
infraction were significant low [75]. In summary, the present results from indirect comparisons should
be reliable and acceptable.
Based on the focus of diagnostic accuracy studies, we identified other common limitations and
insufficiency. Firstly, all the publications included in this analysis were reported on case-control
studies, indicating that the selection bias could possibly lead to over-estimations of diagnostic accuracy
compared with the cross-sectional study and cohort study [76,77]. In addition, the effects of language
selection bias and publication bias cannot be ignored in any meta-analysis [19]. Finally, the detection
utilizing sputum DNA testing was not good enough. We think two methods might have the potential
to screen valid and good biomarkers for the advancement of the field. Firstly, a panel with multiple
methylated genes may be of high performance in diagnostic models. Secondly, instead of qualitative
methods (MSP), quantitative methods for the determination of the methylation patterns in candidate
genes may increase the diagnostic performance.
5. Conclusions
In conclusion, despite these limitations, our meta-analysis advocates that methylated SOX17,
CDO1, ZFP42, TAC1, FAM19A4, FHIT, MGMT, p16, and RASSF1A are useful biomarkers in the
screening and auxiliary detection of lung cancer. Our findings provide new avenues for assessing the
comparative diagnostic effectiveness of several methylations in lung cancer based on the method of
network meta-analysis. Further high-quality and large-scale studies are needed to confirm our analysis.
Supplementary Materials: The following are available online at www.mdpi.com/1660-4601/14/7/679/s1,
Figures S1–S32: Indirect comparisons between one methylated gene and 31 other genes; Table S1: Indirect
comparisons of 32 genes.
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